Alphabet returned to reinvest in the epigenetics diagnostics technology developer through a series D round that took its total funding to about $145m.

UK-based genome sequencing technology developer Cambridge Epigenetix has secured $88m in series D funding on Tuesday from GV, a corporate venturing unit for internet and technology conglomerate Alphabet.

The round was led by Singaporean state-owned investment firm Temasek and also featured Sequoia Capital, Ahren Innovation Capital, Third Point Ventures and New Science Ventures.

Founded in 2012 and spun out of University of Cambridge, Cambridge Epigenetix has developed a diagnostic screening system that uses epigenetics to test for a number of…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn